1. Neuroprotection by pharmacologic blockade of the GAPDH death cascade.
- Author
-
Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, and Snyder SH
- Subjects
- Animals, Antiparkinson Agents pharmacology, Apoptosis physiology, Cell Line, Glyceraldehyde-3-Phosphate Dehydrogenases physiology, Humans, In Vitro Techniques, MPTP Poisoning pathology, MPTP Poisoning physiopathology, Male, Mice, Nerve Degeneration pathology, Nerve Degeneration physiopathology, Nerve Degeneration prevention & control, Nitric Oxide metabolism, Nuclear Proteins physiology, Oxepins pharmacology, Parkinson Disease drug therapy, Selegiline pharmacology, Ubiquitin-Protein Ligases physiology, Apoptosis drug effects, Glyceraldehyde-3-Phosphate Dehydrogenases antagonists & inhibitors, Neuroprotective Agents pharmacology
- Abstract
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) participates in a cell death cascade wherein a variety of stimuli activate nitric oxide (NO) synthases with NO nitrosylating GAPDH, conferring on it the ability to bind to Siah, an E3-ubiquitin-ligase, whose nuclear localization signal enables the GAPDH/Siah protein complex to translocate to the nucleus where degradation of Siah targets elicits cell death. R-(-)-Deprenyl (deprenyl) ameliorates the progression of disability in early Parkinson's disease and also has neuroprotective actions. We show that deprenyl and a related agent, TCH346, in subnanomolar concentrations, prevent S-nitrosylation of GAPDH, the binding of GAPDH to Siah, and nuclear translocation of GAPDH. In mice treated with the dopamine neuronal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), low doses of deprenyl prevent binding of GAPDH and Siah1 in the dopamine-enriched corpus striatum.
- Published
- 2006
- Full Text
- View/download PDF